Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Scinv-you're wasted here. I'm sure these big investment groups would reward you for warning them about investing in a company without a justifiable patent. https://tools.morningstar.co.uk/uk/stockreport/default.aspx?tab=5&vw=own&SecurityToken=0P00007OXV%5D3%5D0%5DE0WWE%24%24ALL&Id=0P00007OXV&ClientFund=0&CurrencyId=BAS
Or even the FDA and EMA might appreciate you to warn them they are wasting their time who have them on track to register (upon successful phase 3 trial) for this indication. You should also advise whichever company snaps them up they are wasting their time. You are full of the smelliest brown stuff imaginable. I can see which ever pharma company you claim to work for won't allow you in their medical affairs department.
@Doc-Clinical trials gov website hasn't been updated since March 3rd(SNG don't control this). https://clinicaltrials.gov/ct2/show/NCT04732949?term=sprinter&draw=2&rank=6
It's likely the centres will say recruiting until the trial has recruited fully. The only way someone will know how many patients have been recruited is by speaking to a PI (Dr in charge of recruiting to any given centre) on the trial or the company running the trial for SNG (pharmaxis)
Scinv-Thank you for sharing those papers but they are not directly relevant to covid but talk to autoimmunity in non respiratory conditions. I take it you haven't seen any of Prof Wilkinsons recent lectures or their biobank work or even why IFN beta 1a was chosen ahead of any of the other IFN type 1. You also don't give any reference to rates of auto antibody to IFN beta as I requested. Yes they share the same receptor as IFN alfa but that makes using IFN beta more important as it can fill the receptor while IFN alpha is being blocked by an auto antibody. I give you points for trying but I'll raise your BSc with a PhD and years of pharma experience.
@Scinv "And just to add, in a large study back in october, when they checked the outcomes all cases with autoantibodies had more severe disease, it just that was only a subset of patients with severe disiease so it is not the only determining factor, but it is *definitely* one."
Please provide a link to this study. Also can you show me the break of what % autoantibody are for each IFN subtype. We have seen in the literature that IFN autoantibodies are expressed in COVID for the alpha variety. Happy to be proven otherwise but I prefer a scientific paper please.
@Prion25. I normally ignore Scinv as he has agenda. I would like to say he is guilty of both being right and wrong. Yes there are autoantibodies to IFN. However, the literature suggests to IFN alpha that about 10% of patients express autoantibodies. There are about 13 types of IFN alpha subtypes. Only 1 IFN beta variety. SNG uses IFN beta currently.
I'm thinking the company with a track record with similar type drugs to VAL201 is Otsuka. Their compound dasatinib is now out of patent. So could be looking at a hopefully new and more specific version. I can't download their pipeline to check if they are interested in women's health.
Val201 mode of action is to block SRC kinase. It won’t be the first drug that targets this receptor in prostate cancer. A drug used in CML (type of blood cancer) got to phase 3 but ultimately proved negative. This is both a positive and negative. The positive is that SRC kinase is seen as a useful target in prostate by interfering with bone mets. Ultimately what PYC will have to show is VAL201 targets the SRC kinase receptor more strongly than dasatinib does. If not then other areas like sepsis and endometriosis will be looked at more. Also it’s likely to be a third line of therapy in prostate cancer will be late down after the patients has exhausted a few other options. But there is still a massive need. https://www.nature.com/articles/nrurol.2013.283
GRACE83-Have you seen AZs cancer pipeline? Its massive. It could be that they are interested in this application more than other areas. There are no real affective treatments for Sepsis. 48k people die in the UK alone from sepsis. It would be a quick trial to run as well compared to most cancer trials. I work in pharma this is just my two pennies worth.
Hi
You may have seen the email that may or may not be real. But the potential of VAL201 in sepsis is a real possibility. For those who don't have a pharma background. VAL201 belongs to the SRC Kinase family. A drug that targets this receptor has also been looked at this in this setting. It is hoped the VAL201 targets this receptor more strongly and if so SEPSIS is a massive unmet need. Possibly much bigger than prostate cancer where there many options.
For those with a scientific interest here is a paper exploring this in more detail.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936983/
SUPPLY- People are worried about supply for activ 2. What people on here don't realise is the rate limiting step is unlikely to be SNG/CMP. Its likely the labelling that needs to be done for trials. Trials labelling takes a long time due to all the various numbers for tracking and other codes you need. This won't be by SNG it will be by the trial coordinator for ACTIV-2 or pharmaxis for phase 3.
EVA-The 80million fund raise was to help production and the phase 3. We have been scaling up production so there will be quite a bit to sell. If ACTIV 2 is positive -The US government will support upscaling manufacture with funds for EUA.
You're the worst deramper ever. Not even subtle.
EVA- You think only a 50% increase on positive phase 3???? This will guarantee FDA, EMA and MHRA access. I would anticipate at least an £8/SP then when orders come in and eventually TO you will see much higher numbers.
Reading your posts I feel you have an ulterior motive.
TWATCHER-Not suggesting its a UK strategy we have more than enough vaccine on order to vaccinate the population several times over. Maybe an option for the countries where COVAX are aiming to supply. There is not enough vaccine to go around in these countries. We know that UK government policy moves with science. Hence why we have the 12 week interval between AZ doses and the data in the over 65s from Scotland that has pushed the EU to reconsider . Anyway I will leave you to it. I'm not sure engaging on LSE with your type is probably worth the time or energy.
TWATCHER-J&J is a single dose option. The AZ, Moderna and Pfizer trials were two dose approaches in COVID naive population. The question that needs to be answered is do you need two doses in a prior COVID patient who already has measurable levels of antibodies? This is being looked at. I imagine in populations where vaccine rationing is taking place it will be a possible option to look at with hopefully antibody tests to show this.
The antibody test makes sense for those who have had covid they can get away with just one vaccine rather than two doses.